Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer

Published:2022-04 Issue: Volume:178 Page:106162
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Gupta Nitasha,Huang Tzu-Ting,Horibata Sachi,Lee Jung-Min

Funder

National Cancer Institute

National Institutes of Health

Doris Duke Charitable Foundation

American Association for Dental, Oral, and Craniofacial Research

Publisher

Elsevier BV

Subject

Pharmacology

Reference86 articles.

1. A decade of clinical development of PARP inhibitors in perspective;Mateo;Ann. Oncol.,2019

2. Trapping of PARP1 and PARP2 by clinical PARP inhibitors;Murai;Cancer Res.,2012

3. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N. Engl. J. Med.,2018

4. PARP inhibitors in the management of ovarian cancer: ASCO guideline;Tew;J. Clin. Oncol.,2020

5. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation;Litton;N. Engl. J. Med.,2018

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on small molecule compounds targeting synthetic lethality for cancer therapy;European Journal of Medicinal Chemistry;2024-11

2. Kaempferol from Alpinia officinarum hance induces G2/M cell cycle arrest in hepatocellular carcinoma cells by regulating the ATM/CHEK2/KNL1 pathway;Journal of Ethnopharmacology;2024-10

3. ATR/Chk1 interacting lncRNA modulates DNA damage response to induce breast cancer chemoresistance;Cell Insight;2024-10

4. Drug combinations of camptothecin derivatives promote the antitumor properties;European Journal of Medicinal Chemistry;2024-09

5. GRK2-mediated AKT activation controls cell cycle progression and G2 checkpoint in a p53-dependent manner;Cell Death Discovery;2024-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3